Works matching IS 25094254 AND DT 2024 AND VI 8 AND IP 6
Results: 16
Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 787, doi. 10.1007/s41669-024-00528-0
- By:
- Publication type:
- Article
Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 935, doi. 10.1007/s41669-024-00521-7
- By:
- Publication type:
- Article
Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 923, doi. 10.1007/s41669-024-00520-8
- By:
- Publication type:
- Article
Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 945, doi. 10.1007/s41669-024-00519-1
- By:
- Publication type:
- Article
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 887, doi. 10.1007/s41669-024-00518-2
- By:
- Publication type:
- Article
A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 793, doi. 10.1007/s41669-024-00517-3
- By:
- Publication type:
- Article
Correction: Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 911, doi. 10.1007/s41669-024-00515-5
- By:
- Publication type:
- Article
Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 869, doi. 10.1007/s41669-024-00514-6
- By:
- Publication type:
- Article
Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 847, doi. 10.1007/s41669-024-00513-7
- By:
- Publication type:
- Article
Economic Impact of Bladder Cancer in the USA.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 837, doi. 10.1007/s41669-024-00512-8
- By:
- Publication type:
- Article
Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 823, doi. 10.1007/s41669-024-00511-9
- By:
- Publication type:
- Article
Clinicians' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 857, doi. 10.1007/s41669-024-00510-w
- By:
- Publication type:
- Article
Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 809, doi. 10.1007/s41669-024-00507-5
- By:
- Publication type:
- Article
Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 6, p. 897, doi. 10.1007/s41669-024-00505-7
- By:
- Publication type:
- Article